Modulation of Interleukin-6/Interleukin-6 receptor cytokine loop in the treatment of multiple myeloma

Leukemia and Lymphoma

Volumn 27, Issue 1-2, 1997, Pages 11-23

  Chen, Y I Hsiang ^a   Shiao, Rei Tsang ^a   Labayog, Jo Mel ^a   Modi, Sanjiv ^a   Lavelle, Donald ^a  

^a NONE

Author keywords

Cytokines; Glucocorticoids; Interferons; Interleukin 6; Myeloma; Retinoids

Indexed keywords

ALPHA INTERFERON; ANTISENSE OLIGONUCLEOTIDE; CARMUSTINE; CYCLOPHOSPHAMIDE; CYTOKINE; DEXAMETHASONE; DOXORUBICIN; GLUCOCORTICOID; GLYCOPROTEIN GP 130; INTERFERON; INTERLEUKIN 6; INTERLEUKIN 6 ANTIBODY; INTERLEUKIN 6 RECEPTOR; MELPHALAN; PREDNISONE; PROTEIN ANTIBODY; RECEPTOR ANTIBODY; RETINOIC ACID; RETINOID; SURAMIN; VINCRISTINE;

CANCER CHEMOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL TRIAL; DOWN REGULATION; DRUG RESPONSE; HUMAN; HUMAN CELL; HYPERCALCEMIA; MAJOR CLINICAL STUDY; MULTIPLE MYELOMA; MYELOMA CELL; PRIORITY JOURNAL; RECEPTOR BINDING; REVIEW; SIGNAL TRANSDUCTION;

EID: 0030776123     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.3109/10428199709068267     Document Type: Review

References (80)

1. Alexanian, R. and Dimipoulos, M. (1994). The treatment of multiple myeloma. N. Engl. J. Med., 330, 484-489.
2. Gregory, W. M., Richard, M. A. and Malpas, J. S. (1992). Combination chemotherapy versus melphalan and prednisone in the treatment of multiple myeloma: An overview of published trials. J. Clin. Oncol., 10, 334-342.
3. Jagannath, S., Vesole, D. H., Glenn, L., Crowely, J. and Barlogie, B. (1992). Low risk intensive therapy for multiple myeloma with combined autologous bone marrow and blood stem cell support. Blood, 80, 1666-1672.
4. Fermand, J-P., Chevert, S., Ravaud, P., et al (1993). Highdose chemoradiotherapy and autologous blood stem cell transplantation in multiple myeloma: Results of a phase II trial involving 63 patients. Blood, 82, 2005-2009.
5. Anderson, K. C., Barut, B. A., Ritz, J., et al. (1991). Monoclonal antibody-purged autologous bone marrow transplantation therapy for multiple myeloma. Blood, 77, 712-720.
6. Attal, M., Harousseau, J.-L., Stoppa, A.-M., et al. (1996). A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N. Engl. J. Med., 335, 91-97.
7. Barlogie, B., Epstein, J., Selvanayagam, P. and Alexanian, R. (1989). Plasma cell myeloma-New biological insights and advances in therapy. Blood, 73, 865-879.
8. Mandelli, F., Avvisati, G. and Tribalto, M. (1992). Biology and treatment of multiple myeloma. Curr. Opinion in Oncol., 4, 73-86.
9. Klein, B., Zhang, X.-G., Lu, Z.-Y. and Bataille, R. (1995). Interleukin-6 in human multiple myeloma. Blood, 85. 863-872.
10. Chen, Y.-H., Desai, P., Shiao, R.-T., Lavelle, D., Haleem, A. and Chen, J. (1996). Inhibition of myeloma cell growth by dexamethasone and all-trans retinoic acid: Synergy through modulation of interleukin-6 autocrine loop at multiple sites. Blood, 87, 314-323.
11. Kawano, M., Hirano, T., Matsuda, T., et al. (1988). Autocrine generation and requirement of BSF-2/IL-6 for human myelomas. Nature, 332, 83-85.
12. Anderson, K. C., Jones, R. M., Morimoto, C., Leavitt, P. and Barut, B. A. (1989). Response patterns of purified myeloma cells to hematopoietic growth factors. Blood, 73, 1915-1924.
13. Freeman, G. J., Freeman, A. S., Rabinowe, S. N., et al. (1989). Interleukin 6 gene expression in normal and neoplastic B-cells. J. Clin. Invest., 83, 1512-1518.
14. Schwab, G., Siegall, C. B., Aarden, L. A., Neckers, L. M. and Nordan, R. P. (1991). Characterization of an interleukin-6-mediated autocrine growth loop in the human myeloma cell line, U266. Blood, 77, 587-593.
15. Levy, Y., Tsapis, A. and Brouet, J.-C. (1991). Interleukin-6 antisense oligonucleotides inhibit the growth of human myeloma cell lines. J. Clin. Invest., 88, 696-699.
16. Portier, M., Rajzbaum, G., Zhang, X.-G., et al. (1991). In vivo interleukin 6 gene expression in the tumoral environment in multiple myeloma. Eur. J. Immunol, 21, 1759-1762.
17. Klein, B., Zhang, X.-G., Jourdan, M., et al. (1989). Paracrine rather than autocrine regulation of myeloma-cell growth and differentiation by interleukin-6. Blood, 73, 517-526.
18. Akira, S., Taga, T. and Kishimoto, T. (1993). Interleukin-6 in biology and medicine. Adv. Immunol., 54, 1-78.
19. Lokhorst, H. M., Lamme, T., de Smet, M., et al. (1994). Primary tumor cells of myeloma patients induce interleukin-6 secretion in long-term bone marrow cultures. Blood, 84, 2269-2277.
20. Bataille, R., Jourdan, M., Zhang, X.-G. and Klein, B. (1989). Serum levels of interleukin 6, a potent myeloma cell growth factor, as a reflect of disease severity in plasma cell dyscrasias. J. Clin. Invest., 84, 2008-2011.
21. Reibnegger, G., Krainer, M., Herold, M., Ludwig. H., Wachter, H. and Huber, H. (1991). Predictive value of interleukin-6 and neopterin in patients with multiple myeloma. Cancer Res., 51. 6250-6253.
22. Bergui, L., Schena, M., Gaidano, G., Riva. M. and Caligaris-Cappio, F. (1989). Interleukin 3 and interleukin 6 synergistically promote the proliferation and differentiation of malignant plasma cell precursors in multiple myeloma. J Exp, Med., 170, 613-618.
23. Caligaris-Cappio, F., Bergui, L., Gregoretti, M. G., et al. (1991). Role of bone marrow stromal cells in the growth of human multiple myeloma. Blood, 77, 2688-2693.
24. Zhang, X.-G., Bataille, R., Jourdan. M., Saeland, S., Banchereau, J. and Mannoni, P. (1990). Granulocytemacrophage colony-stimulating factor synergies with interleukin-6 in supporting the proliferation of human myeloma cells. Blood, 76, 2599-2605.
25. Lu, Z. Y., Zhang, X. G., Rodriguez, C., et al (1995). Interleukin-10 is a proliferation factor but not a differentiation factor but not a differentiation factor for human myeloma cells. Blood, 85, 2521-2527.
26. Kishimoto, T., Akira, S., Narazaki, M. and Taga, T. (1995). Interleukin-6 family of cytokines and gp130. Blood, 86, 1243-1254.
27. Pelliniemi, T.-T., Irjala, K., Manila, K., et al. (1995). Immunoreactive interleukin-6 and acute phase proteins as prognostic factors in multiple myeloma. Blood, 85, 765-771.
28. Chen, Y.-H. and Magalhaes, M. C. (1990). Hypoalbuminemia in patients with multiple myeloma. Arch. Intern. Med., 150, 605-610.
29. Ohtani, K., Ninomiya, H., Hasegawa, Y., et al. (1995). Clinical significance of elevated soluble interleukin-6 receptor levels in the sera of patients with plasma cell dyscrasias. Brit. J. Haematol., 91, 116-120.
30. Klein, B., Wijdenes, J., Zhang, X.-G., et al. (1991). Murine anti-interleukin-6 monoclonal antibody therapy for a patient with plasma cell leukemia. Blood, 78, 1198-1204.
31. Manolagas, S. C. and Jilka, R. L. (1995). Bone marrow, cytokines, and bone remodeling. N. Engl. J. Med., 332, 305-311.
32. Bataille, R., Chappard, D., Marcelli, C., et al. (1991). Recruitment of new osteoblasts and osteoclasts is the earliest critical event in the pathogenesis of human multiple myeloma. J. Clin. Invest., 88, 62-66.
33. Bataille, R., Chappard, D. and Klein, B. (1992). Mechanisms of bone lesions in multiple myeloma. Hematol. Oncol. Clin. North. Amer., 6, 285-295.
34. Mundy, G., Raisz, L. G., Cooper, R. A., Schechter, G. P. and Salmon, S. E. (1974). Evidence for the secretion of an osteoclast stimulating factor in myeloma. N. Engl. J. Med., 291, 1041-1046.
35. Pulkki, K., Pelliniemi, T-T., Rajamaki, A., Tienhaara, A., Laakso, M. and Lahtinen, R. (1996). Soluble interleukin-6 receptor as a prognostic factor in multiple myeloma. Brit. J. Haematol, 92, 370-374.
36. Gaillard, J.-P., Bataille, R., Brailly, H., et al (1993). Increased and highly stable levels of functional soluble interleukin-6 receptor in sera of patients with monoclonal gammopathy. Eur. J. Immunol., 23, 820-824.
37. Tamura, T., Udagawa, N., Takahashi, N., et al. (1993). Soluble interleukin-6 receptor triggers osteoclast formation by interleukin-6. Proc. Natl. Acad. Sci. USA., 90, 11924-11928.
38. Schwabe, M., Brini, A. T., Bosco, M. C., et al. (1994). Disruption by interferon-α of an autocrine interleukin-6 growth loop in IL-6-dependent U266 myeloma cells by homologous and heterologous down-regulation of the IL-6 receptor α- and β-chains. J. Clin. Invest., 94, 2317-2325.
39. Anthes, J. C., Zhan, A., Gilchrist, H., Egan, R. W., Siegel, M. I. and Billah, M. M. (1995). Interferon-α down-regulates the interleukin-6 receptor in a human myeloma cell line. U266, Biochem. J., 309, 175-180.
40. Lasfar, A., Wietzerbin, J. and Billard, C. (1994). Differential regulation of interleukin-6 receptors by interleukin-6 and interferons in multiple myeloma cell lines. Eur. J. Immunol., 24, 124-130.
41. Tanaka, H., Tanabe, O., Iwato, K., et al (1989). Sensitive inhibitory effect of interferon-alpha on M-protein secretion on human myeloma cells. Blood, 74, 1718-1722.
42. Jernberg-Wiklund, H., Pettersson, M. and Nilsson, K. (1991). Recombinant interferon-γ inhibits the growth of JL-6-dependent human multiple myeloma cell lines in vitro. Eur. J. Haematol., 46, 231-239.
43. Portier, M., Zhang, X.-G., Caron, E., Lu, Z.-Y., Bataille, R. and Klein, B. (1993). γ-interferon in multiple myeloma: Inhibition of interleukin-6 (IL-6)-dependent myeloma cell growth and downregulation of IL-6-receptor expression in vitro. Blood, 81, 3076-3082.
44. Palumbo, A., Battaglio, S., Napoli, P., et al. (1994). Recombinant interferon-γ inhibits the in vitro proliferation of human myeloma cells. Brit. J. Haematol, 86, 726-732.
45. Palumbo, A., Bruno, B., Boccadoro, M. and Pileri, A. (1995). Interferon-γ in multiple myeloma. Leukemia and Lymphoma, 18, 215-219.
46. McIntyre, O. S., Pajak, T. F., Kyle, R. A., Cornwell, G. G., III and Leone, L. (1985). Response rate and survival in myeloma patients receiving prednisone alone. Med. Pediatr. Oncol., 13, 239-243.
47. Ishikawa, H., Tanaka, H., Iwato, K., et al (1991). Effect of glucocorticoids on the biologic activities of myeloma cells: Inhibition of interleukin-1β osteoclast activating factor-induced bone resorption. Blood, 75, 715-720.
48. Gomi, M., Moriwaki, K., Katagiri, S., Kurata, Y. and Thompson, E. B. (1990). Glucocorticoid effects on myeloma cells in culture: Correlation of growth inhibition with induction of glucocorticoid receptor messenger RNA. Cancer Res., 50, 1873-1878.
49. Shiao, R.-T., Miglietta, L., Khera, S. Y., Wolfson, A. and Freter, C. E. (1995). Dexamethasone and suramin inhibit cell proliferation and interleukin-6-mediated immunoglobulin secretion in human lymphoid and multiple myeloma cell lines. Leukemia and Lymphoma, 17, 484-494.
50. Shiao, R.-T., Mcleskey, S. B., Khera, S. Y., Wolfson, A. and Freter, C. E. (1996). Mechanisms of inhibition of IL-6-mediated immunoglobulin secretion by dexamethasone and suramin in human lymphoid and myeloma cell lines. Leukemia and Lymphoma, 21, 293-303.
51. Hardin, J., MacLeod, S., Girgorieva, I., et al. (1994). Interleukin-6 prevents dexamethasone-induced myeloma cell death. Blood, 84, 3063-3070.
52. Moali, P. A., Pillay, S., Weiner, D., Leikin, R. and Rosen, S. T. (1992). A mechanism of resistance to glucocorticoids in multiple myeloma: Transient expression of a truncated glucocorticoid receptor mRNA. Blood, 79,213-222.
53. Ray, A., Zhang, D.-H., Siegel, M. D. and Ray, P. (1995). Regulation of interleukin-6 gene expression by steroids. In: Interleukin-6 Type Cytokines (eds.) Mackiewicz, A., Koj, A., and Sehgal. P. B. vol. 762, pp. 79-88. (Acad. Sci., Ann. N.Y.).
54. Sidell, N., Taga, T., Hirano, T., Kishimoto, T. and Saxon, A. (1991). Retinoic acid-induced growth inhibition of a human myeloma cell line via down-regulation of IL-6 receptors. J. Immunol., 146, 3809-3814.
55. Levy, Y., Labaume, S., Colombel, M. and Brouet, J. C. (1996). Retinoic acid modulates the in vivo and in vitro growth of IL-6 autocrine human myeloma cell lines via induction of apoptosis. Clin. Exp. Immunol., 104, 167-172.
56. Ogata, A., Nishimoto, N., Shima, Y., Yoshizaki, K. and Kishimoto, T. (1994). Inhibitory effect of all-trans retinoic acid on the growth of freshly isolated myeloma cells via interference with interleukin-6 signal transduction. Blood, 84, 3040-3046.
57. Pulkki, K., Neva, M., Koskela, K., Ollikainen, H., Remes, K. and Pelliniemi, T.-T. (1995). IL-6 receptor-mediated growth inhibition by all-trans retinoic acid but not by interferon-α in human myeloma cells. In: Interleukin-6 Type Cytokines (eds. Mackiewicz, A., Koj, A., and Sehgal, P. B.) vol. 762, pp. 457-458. (Acad. Sci.: Ann. N. Y.).
58. Strassmann, G., Fong, M., Freter, C. E., Windsor, D., D' Alessandro, F. and Nordan, R. P. (1993). Suramin interferes with interleukin-6 receptor binding in vitro and inhibit colon26 mediated experimental cancer cachexia in vivo., J. Clin. Invest., 92, 2152-2159.
59. Taylor, C. W., Lui, R. and Salmon, S. E. (1992). Effects of suramin on in vitro growth of fresh human tumors. J. Natl. Cancer Inst., 84, 489-494.
60. Stein, C. A. (1993). Suramin: a novel antineoplastic agent with multiple potential mechanisms of action. Cancer Res., 53, 2239-2248.
61. Suzuki, H., Yasukawa, K., Saito, T., et al. (1992). Anti-human interleukin-6 receptor antibody inhibits human myeloma growth in vivo. Eur. J. Immunol., 22, 1989-1993.
62. Sporeno, E., Savino, R., Ciapponi, L., et al (1996). Human interleukin-6 receptor super-antagonists with high potency and wide spectrum on multiple myeloma cells. Blood, 87, 4510-4519.
63. Demartis, A., Bernassola, F., Savino, R., Melino, G. and Ciliberto. G. (1996). Interleukin 6 receptor superantagonists are potent inducers of human multiple myeloma cell death. Cancer Res., 56, 4213-4218.
64. Morphological, biochemical, and flow cytometric assays of apoptosis. (1991). In: Curr. Protocols in Immunol. (eds. Coligan, J. E., Kruisbeek, A. M., Margulies, D. M., Shevach, E. M., and Strober, W.) pp 3.17. 1-3. 17.14. (John Wiley and Sons, Inc).
65. Kumar, R. and Pelletier, D. (1992). Augmentation of interferon-mediated growth inhibitory and gene inducing responses of human hematopoietic tumor cell lines. Prof. Am. Asso. Cancer Res., 33, 74. (abstr.)
66. Siegel, D., Niesvizky, R., Miller, W. H., Jr.. Busquets, X., Kumar, R. and Michaeli, J. (1992). All trans retinoic acid (ATRA) and interferonα (INFα) synergistically inhibit myeloma cell growth and induce retinoic acid receptor a (RARα) expression. Blood, 80 (suppl.), 121a. (abstr.)
67. Alexanian, R., Dimopoulos, M. A., Delasalle, K. and Barlogie, B. (1992). Primary dexamethasone treatment of multiple myeloma. Blood. 80. 887-890.
68. Salmon, S. E., Croweley, J. J., Grogan, T. M., Finley, P., Pugh. R. P. and Barlogie, B. (1994). Combination chemotherapy, glucocorticoids, and interferon alfa in the treatment of multiple myeloma: A southwest oncology group study. J. Clin Oncol., 12, 2405-2414.
69. Cooper, M. R. (1991). A review of the clinical studies of alpha-interferon in the management of multiple myeloma. Sem. Oncol., 18 (suppl 7), 18-29.
70. Cooper, M. R., Dear, K., McIntyre, O. R., et al. (1993). A randomized clinical trial comparing melphalan/prednisone with or without interferon alfa-2b in newly diagnosed patients with multiple myeloma: A cancer and leukemia group B study. J. Clin. Oncol., 11. 155-110.
71. Oken, M. M., Kyle, R. A., Greipp, P. R. et al. (1992). Possible survival with chemotherapy plus Interferon (rhINF α 2) in the treatment of multiple myeloma. Proc. Am. Soc: Clin. Oncol., 11,358. (abstr.)
72. Osterborg, A., Bjokholm, M., Bjoreman, M., et al (1993). Natural interferon-α in combination with melphalan/prednisone versus melphalan/prednisone in the treatment of multiple myeloma stages II and III: A randomized study from the myeloma group of central sweden. Blood. 81. 1428-1434.
73. Mandelli, F., Avvisati, G., Amadori, S., et al (1990). Maintenance treatment with recombinant Interferon alfa-2b in patients with multiple myeloma responding to conventional induction chemotherapy. N. Engl. J. Med., 322, 1430-1434.
74. Browman, G. P., Bergsagel. D., Sicheri, D., et al. (1995). Randomized trial of interferon maintenance in multiple myeloma: A study of the national cancer institute of canada clinical trails group. J. Clin. Oncol., 13, 2354-2360.
75. Niesvizky, R., Siegel, D. S., Busquets, X., et al. (1995). Hypercalcemia and increased serum interleukin-6 levels induced by all-trans retinoic acid in patients with multiple myeloma. Brit. J. Haematol., 89. 217-218.
76. Vesole, D., Kornbluth, J., Jagannath. S., et al. (1993). Biological response modifiers (BRM) in refractory multiple myeloma (MM): Lack of clinical efficacy of recombinant human interleukin-4 (rhIL-4) and all-trans retinoic acid (ATRA). Blood. 82 (suppl). 263a. (abstr.)
77. Musto, P., Falcone, A., Sajeva, M. S., D'Arena, G., Bonini, A. and Carotenuto, M. (1994). All-trans retinoic acid for advanced multiple myeloma. Blood, 85, 3769-3770.
78. Musto, P., Sajeva, M. R., Falcone. A., et al. (1996). In vivo effects of all-trans retinoic acid (ATRA), as single agent or in association with alfa-interferon (INF) and high dose dexamethasone (HDDEX), in patients with advanced multiple myeloma (MM). Haematologica (Pavia). 4th Cong. Italian Soc: Exp. Hematol. (abstr.)
79. Bataille, R., Barlogie, B., Lu, Z. Y., et al. (1995). Biologic effects on anti-interleukin-6 murine monoclonal antibody in advanced multiple myeloma. Blood. 86, 685-691.
80. Chen, Y., Feng, X.-X. and Hagen, K. (1996). Usefulness of flow cytometric detection of cell surface interleukin-6 receptors in human myeloma cell lines. Clin. Lab. Haematol., 18, 161-169.